| 摘要 |
The present invention is particularly directed to the use of a derivative of vinblastine, 3',4'-dehydrovinblastine (3',4'-anhydrovinblastine: AHVB), which differs from vinblastine in that it possesses a double bond at the 3',4' position of the catharanthine nucleus rather than the hydroxyl group that is present in the parent structure, in the treatment of cancer.
|
